Lincoln Pharmaceuticals Ltd. Results

H1FY25 Half Yearly Result Announced for Lincoln Pharmaceuticals Ltd.

Pharmaceuticals company Lincoln Pharmaceuticals announced H1FY25 results Total Income: Rs 328.88 crore compared to Rs 307.99 crore during H1FY24, change 6.78%. EBITDA: Rs 71.50 crore compared to Rs 68.25 crore during H1FY24, change 4.76%. Profit before Tax: Rs 64.26 crore compared to Rs 62.32 crore during H1FY24, change 3.11%. PAT: Rs 50.03 crore compared to Rs 46.52 crore during H1FY24, change 7.55%. EPS: Rs 24.96 for H1FY25. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals, said: “We are pleased to report continued strong growth across all business verticals H1FY25, while maintaining a net debt-free status. Our new product launches in domestic and export markets have strengthened our market presence and accelerated growth, positioning us for even better performance during the second half of the year. Through a combination of robust growth initiatives, highquality products, geographic expansion, and operational improvements, we are on track to achieve our ambitious Rs 750 crore revenue target by FY26. Notably, we are among a select group of companies that have consistently achieved profit growth every year from FY13 to FY24.”